Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of HS-10511 in Healthy Subjects
NCT06210607Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing HS-10511 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events (AE) and serious adverse events (SAE), Number of participants with clinically significant change from baseline in vital signs and 3 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
HS-10511
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06210607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210607.